专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明专利

CA2469266A1 THE METHOD OF TREATING CANCER 未知
公开(公告)号：CA2469266A1
公开(公告)日：2003-06-19
申请号：CA2469266
申请日：2002-12-10
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K47/04 , A61K35/74 , A61K39/04 , A61K39/39 , A61K47/06 , A61K47/18 , A61K47/26 , A61K47/38 , A61K47/42 , A61P35/00 , A61P35/04 , A61K35/66
摘要： Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from "Mycobacterium w' (Mw) is found to be useful in the management of cancer. We have now found that the same therapeutic agent is useful in management of cancer. The use of Mycobacterium w containing formulations is associated with decrease in burden of cancer tissue, decreasing symptoms associated with cancer and improving quality of life. It also improves tolerance to other therapies.

82. 发明专利

AP2002002452A0 The method of treating drug resistant mycobacterium tuberculosis infection. 未知
公开(公告)号：AP2002002452A0
公开(公告)日：2002-06-30
申请号：AP2002002452
申请日：2001-06-26
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K31/43 , A61K31/4409 , A61P31/06
摘要： Multidrug resistance to anti-tuberculous drugs poses threat in the treatment of tuberculosis. These strains are resistant to at least tow first line anti-tuberculous drugs such as inh and rifampicin. Frequently, such mdr strains show resistance to all commonly used firstline agents i.E inh, rifampicin, streptomycin, ethambutol and pyrazinamide. Isoniazid is the most widely used anti-tuberculous drug. Resistance to isoniazid can occur by increased expression on inha or by mutations that lower the enzyme's affinity to nadh. Mutatios in katg, which encodes catalase peroxidase, is the most common source of resistance. Another mechanism of isoniazid resistance occurs by defects in nadh dehydrogenase (ndh)of the respiratory chain.INcreases expression of ahpc has been suggested as another mechanism of inh resistance in mycobacteria. The present invention provides method of treating drug resistance for mycobacterium tuberculosis infection. According to present invention, a method is provided to employ penicillin with inh. This reduces the mic of inh and makes resistant organisms sensitive. The level of penicillins required for reversal of inh resistance is kown to be achieved and maintained by therapeutic doses of penicillins.

83. 发明专利

ID28121A 未知
公开(公告)号：ID28121A
公开(公告)日：2001-05-03
申请号：ID20002252
申请日：2000-02-02
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K9/00 , A61K47/32 , A61K47/36

84. 发明专利

AP2000001977A0 The process for manufacturing topical opthalmic preparations without systemic effects. 未知
公开(公告)号：AP2000001977A0
公开(公告)日：2000-12-31
申请号：AP2000001977
申请日：2000-02-02
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K9/00 , A61K47/32 , A61K47/36
摘要： For treating eye diseases, various kinds of medications are used. They are used in form of topical preparations or in form of systemic preparations to be taken orally or parenterally. Of topical preparations some are for topical use only e.g. framycetin, neomycin, loteprednol ebanoate, etc. However, large majority of topical ophthalmic drugs are for systemic use also, e.g.. Ciprofloxacin, gentamicin, timolol, clonidine, dexamethasone, betamethasone, carbachol, etc. Some of these drugs when used topically are also found to have systemic effects and if they are of serious nature limits the use of that drug, e.G. cardiopulmonary effects of b-blockers like timolol. Dryness of mouth, flush, fever, tachy cardia, urinary retention, convulsion irritability with atropine. Hypertension with phenylephine. Increased alivation, nausea, vomiting, diarrhea, stomach cramps, bronchial secretions, bronchial constriction, asthma, bradycardia, paresthesia with miotics, hypotension with clonidine. Dry mouth, fatigue and drowsiness with apraclonidine and brimonidine.

85. 发明专利

AU2541199A The process for manufacturing formulation of topical beta blockers with improvedefficacy 未知
公开(公告)号：AU2541199A
公开(公告)日：2000-07-03
申请号：AU2541199
申请日：1999-03-04
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K31/13 , A61K9/00 , A61K31/138 , A61K31/216 , A61K31/4704 , A61K31/5355 , A61K31/78 , A61K47/00

86. 发明专利

CA2354765A1 THE PROCESS FOR MANUFACTURING FORMULATION OF TOPICAL BETA BLOCKERS WITH IMPROVED EFFICACY 未知
公开(公告)号：CA2354765A1
公开(公告)日：2000-06-22
申请号：CA2354765
申请日：1999-03-04
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K31/13 , A61K9/00 , A61K31/138 , A61K31/216 , A61K31/4704 , A61K31/5355 , A61K31/78 , A61K47/00
摘要： Beta blockers are used as topical ophthalmic preparation for reducing Intra Ocular Pressure. B-blocker used for this purpose include timolol, levobunolo l, carteolol, metipranalol. They reduce the aqueous production and thereby redu ce I.O.P. They are commonly used as drops. Efficacy of topical B-blockers is dependent on concentration of drug in formulation. However, increasing the concentration of drug beyond approved dosage forms does not increase the efficacy significantly e.g. Timolol 0.5% has identical pressure lowering capacity as 1% Timolol. The attempts to improve pressure reduction efficienc y of B-blockers has not met with success so far. The sustained release formulation of Timolol (Timolol XE) has resulted in amount of drug to achiev e same therapeutic effect. However, none of the formulation has improved efficacy of drug for reducing I.O.P. The present invention relates to the process of manufacturing such formulation of B-blocker which improves its I.O.P lowering effect. The formulation so prepared is non-irritating and wel l tolerated. The process of manufacturing new formulation with improved effica cy involves use of carboprolol and preservative. The timolol 0.5% gel formulate d using process was evaluated in normal as well as glaucomatous eyes. The reduction in I.O.P. is found to be approx. 15% more than found with drops in normal individuals. Similar findings are also observed in glaucomatous eyes.

87. 发明专利

AP2001A Immunomodulator for the management of human immunodeficiency virus (HIV) disease/infection. 未知
公开(公告)号：AP2001A
公开(公告)日：2009-05-11
申请号：AP2003002847
申请日：2002-01-17
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K35/74 , A61P31/18 , A61P37/02
摘要： Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides immunomodulator based on Mycobaclerium w. Its use in associated with symptomatic improvement as well as improvement in immunity as evidenced by improved CD4 count in HIV infected individuals.

88. 发明专利

AP1896A The method of treating cancer 未知
公开(公告)号：AP1896A
公开(公告)日：2008-10-08
申请号：AP2004003070
申请日：2002-12-10
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K47/04 , A61K35/74 , A61K39/00 , A61K39/04 , A61K39/39 , A61K47/06 , A61K47/18 , A61K47/26 , A61K47/38 , A61K47/42 , A61P35/00 , A61P35/04
摘要： Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from "Mycobactcrium w' (Mw) is found to be useful in the management of cancer. We have now found that the same therapeutic agent is useful in management of cancer. The use of Mycobactcrium w containing formulations is associated with decrease in burden of cancer tissue, decreasing symptoms associated with cancer and improving quality of life. It also improves tolerance to other therapies.

89. 发明专利

AP2004003109A0 Method of providing prophylaxis for tuberculosis in HIV positive individuals 未知
公开(公告)号：AP2004003109A0
公开(公告)日：2004-09-30
申请号：AP2004003109
申请日：2003-01-27
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K39/04 , A61P31/06 , A61P35/00
摘要： Present invention relates to the method providing prophylaxis for tuberculosis in hiv positive indiduals. According to present invention, vaccine made from 'Mycobacterium w' (Mw) is found to be useful in prophylaxis against tuberculosis in HIV positive individuals.

90. 发明专利

DK1137407T3 未知
公开(公告)号：DK1137407T3
公开(公告)日：2004-05-10
申请号：DK99905124
申请日：1999-03-04
申请人： KHAMAR BAKULESH MAFATLAL
发明人： KHAMAR BAKULESH MAFATLAL
IPC分类号： A61K31/13 , A61K9/00 , A61K31/138 , A61K31/216 , A61K31/4704 , A61K31/5355 , A61K31/78 , A61K47/00 , A61P27/02

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式